442-52-4
基本信息
吡咯咪唑盐酸盐
1-[(4-氯苯基)甲基]-2-(吡咯烷-1-基甲基)苯并咪唑
1-(4-CHLOROBENZYL)-2-(PYRROLIDIN-1-YLMETHYL)-1H-BENZO[D]IMIDAZOLE HYDROCHLORIDE
Depocural
Histakool
NSC 46261
Lergopenin
1-p-Chlorobenzyl-2-pyrrolidino-methylbenzimidazole
1-(p-Chlorobenzyl)-2-pyrrolidylmethylenebenzimidazole
1-p-Chlorobenzyl-2-[1-pyrrolidinylmethyl] benzimidazole
1-(4-Chlorobenzyl)-2-(pyrrolizinomethyl)-1H-benzimidazole
1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)benzimidazole
物理化学性质
| 熔点 | 239-241℃ |
| 沸点 | 506.1±40.0 °C(Predicted) |
| 密度 | 1.25±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | insoluble in H2O; ≥16.2 mg/mL in DMSO; ≥95.8 mg/mL in EtOH |
| 酸度系数(pKa) | 9.08±0.20(Predicted) |
| 形态 | 固体 |
| 颜色 | White to off-white |
| InChI | InChI=1S/C19H20ClN3/c20-16-9-7-15(8-10-16)13-23-18-6-2-1-5-17(18)21-19(23)14-22-11-3-4-12-22/h1-2,5-10H,3-4,11-14H2 |
| InChIKey | CJXAEXPPLWQRFR-UHFFFAOYSA-N |
| SMILES | C1(CN2CCCC2)N(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2N=1 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P264-P280-P302+P352-P321-P332+P313-P362-P305+P351+P338-P337+P313-P261-P271-P304+P340-P312-P403+P233-P405-P501 |
制备方法
622-95-7
2948-92-7
442-52-4
在氮气保护下，将化合物10（0.24 mmol，49 mg）溶解于新蒸馏的四氢呋喃（THF，0.75 mL）中，随后冷却至0℃。向该溶液中缓慢加入60%氢化钠（NaH）的油分散液（0.36 mmol，14.4 mg），并在0℃下搅拌反应混合物5分钟。接着，加入4-氯苄基溴（0.26 mmol，54 mg）和四丁基碘化铵（TBAI，0.024 mmol，9 mg）。将反应混合物在室温下搅拌过夜。反应完成后，用水（2 mL）和乙酸乙酯（EtOAc，5 mL）稀释反应混合物。分离水相，并用乙酸乙酯（每次5 mL）萃取两次。合并有机相，用无水硫酸镁（MgSO4）干燥，过滤后减压浓缩。通过硅胶柱色谱法（洗脱剂：乙酸乙酯）纯化粗产物，得到目标化合物11，为无色固体，产率65%（51 mg），熔点101-102℃。1H NMR（300 MHz，CDCl3）δ 7.83-7.77（m，1H），7.32-7.22（m，5H），7.06（d，J = 8.7 Hz，2H），5.58（s，2H），3.90（s，2H），2.58（m，4H），1.76（m，4H）；13C NMR（75 MHz，CDCl3）δ 152.3，142.5，135.9，135.3，133.6，129.1（2C），128.1（2C），122.9，122.7，120.0，109.7，54.8（2C），53.2，46.8，23.7（2C）；HRMS（ESI）：计算值C19H21N3Cl [M + H]+：326.1424，实测值326.1427；FTIR（neat，cm-1）2958，2927，2875，2810，1488，1463，1403，1294，1088，1034，1014，742，487。
参考文献：
[1] Tetrahedron, 2015, vol. 71, # 4, p. 700 - 708
[2] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 21, p. 6788 - 6795
常见问题列表
| Target | Value |
|
H1 receptor
() | |
|
TRPC5
() |
Clemizole hydrochloride is found to inhibit HCV RNA replication in cell culture that is mediated by its suppression of NS4B’s RNA binding, with little toxicity for the host cell. The EC 50 of Clemizole on the W55R mutant J6/JFH RNA is ~18 µM (2.25 times the EC 50 of the wild-type RNA). Clemizole is a novel inhibitor of TRPC5 channels. Clemizole efficiently blocks TRPC5 currents and Ca 2+ entry in the low micromolar range (IC 50 =1.0-1.3 µM). Clemizole exhibits a six-fold selectivity for TRPC5 over TRPC4β (IC 50 =6.4 µM), the closest structural relative of TRPC5, and an almost 10-fold selectivity over TRPC3 (IC 50 =9.1 µM) and TRPC6 (IC 50 =11.3 µM). Clemizole hydrochloride as a novel blocker of TRPC5 with a half-maximal inhibitory concentration of 1.1 µM. The concentration-response curves confirmed a concentration-dependent block of TRPC5 by Clemizole and revealed an apparent IC 50 of 1.1±0.04 µM.
Clemizole hydrochloride has an unexpectedly short plasma half-life (measured at 0.15 hours); it is very rapidly biotransformed into a glucuronide (M14) and a dealkylated metabolite (M12) and into a variety of lesser metabolites in C57BL/6J mice.
吡咯咪唑价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-30234 | 吡咯咪唑 Clemizole | 442-52-4 | 5 mg | 500元 |
| 2026/09/15 | HY-30234 | 吡咯咪唑 Clemizole | 442-52-4 | 10 mg | 800元 |
| 2026/07/06 | S6410 | 吡咯咪唑 Clemizole | 442-52-4 | 5mg | 794.57元 |